INZY
NASDAQInozyme Pharma Inc.
Price$4.00+0.02 (+0.50%)
2025-06-042025-06-30
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inozyme Pharma Inc.SCHEDULE 13G/A - Inozyme Pharma, Inc. (0001693011) (Subject)
- SECSEC Form 15-12G filed by Inozyme Pharma Inc.15-12G - Inozyme Pharma, Inc. (0001693011) (Filer)
- INSIDERSVP, CFO & Head of BD Subramanian Sanjay closing all direct ownership in the company (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERCOO Winton Matthew closing all direct ownership in the company (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERDirector Bolte Axel closing all direct ownership in the company (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERSEC Form 4 filed by Director Sullivan Lynne Marie4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERCEO & Chairman Treco Douglas A closing all direct ownership in the company (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERSEC Form 4 filed by Director Hopfner Robert Lorne4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- SECSEC Form EFFECT filed by Inozyme Pharma Inc.EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form EFFECT filed by Inozyme Pharma Inc.EFFECT - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form 25-NSE filed by Inozyme Pharma Inc.25-NSE - Inozyme Pharma, Inc. (0001693011) (Subject)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form S-8 POS filed by Inozyme Pharma Inc.S-8 POS - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form POS AM filed by Inozyme Pharma Inc.POS AM - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECSEC Form POS AM filed by Inozyme Pharma Inc.POS AM - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECInozyme Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update8-K - Inozyme Pharma, Inc. (0001693011) (Filer)
- SECAmendment: SEC Form SC 14D9/A filed by Inozyme Pharma Inc.SC 14D9/A - Inozyme Pharma, Inc. (0001693011) (Subject)
- SECAmendment: SEC Form SC TO-T/A filed by Inozyme Pharma Inc.SC TO-T/A - Inozyme Pharma, Inc. (0001693011) (Subject)
- PRBioMarin Announces Completion of Acquisition of InozymeSAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha
- INSIDERCOO Winton Matthew was granted 14,355 shares, increasing direct ownership by 194% to 21,743 units (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
- INSIDERCEO & Chairman Treco Douglas A was granted 2,815 shares, increasing direct ownership by 7% to 43,861 units (SEC Form 4)4 - Inozyme Pharma, Inc. (0001693011) (Issuer)
INZY FAQ
7 questionsWhat does Inozyme Pharma Inc. do?
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Where does INZY stock trade?
Inozyme Pharma Inc. (INZY) is listed on NASDAQ.What sector and industry is INZY in?
Inozyme Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Inozyme Pharma Inc. go public?
Inozyme Pharma Inc. (INZY) completed its IPO in 2020.What are analysts saying about INZY?
Inozyme Pharma Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Outperform with a $2600.00 price target on 2024-12-12.What companies are similar to INZY?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare INZY side-by-side with any of them on Quantisnow.How can I track INZY on Quantisnow?
Quantisnow aggregates Inozyme Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INZY to receive live email and push alerts on every new disclosure.